Zebra Medical Vision

Zebra Medical VisionZebra Medical Vision
Zebra Medical Vision

Zebra Medical Vision

Zebra Medical Vision develops AI-powered medical imaging analysis tools to help radiologists detect and diagnose diseases earlier.

DR 532014Active56Shefayim, Israel
Rate

About

Zebra Medical Vision is a medical imaging insight platform that leverages vast clinical data sets and deep learning techniques to build algorithms. These algorithms automatically detect and diagnose medical conditions from imaging scans, aiming to assist radiologists in identifying diseases earlier and more efficiently.
Frequently asked

What does Zebra Medical Vision do?

Zebra Medical Vision is a medical imaging insight platform that leverages vast clinical data sets and deep learning techniques to build algorithms. These algorithms automatically detect and diagnose medical conditions from imaging scans, aiming to assist radiologists in identifying diseases earlier and more efficiently.

What is Zebra Medical Vision's revenue?

StartupHub estimates Zebra Medical Vision's annual revenue at $10.6M (range $6.6M to $15.7M, 66% confidence), based on comparable companies in the sector.

What is Zebra Medical Vision's valuation?

StartupHub estimates Zebra Medical Vision's effective valuation at $202.6M (range $125.0M to $300.0M, 10% confidence), based on comparable companies in the sector.

How much funding has Zebra Medical Vision raised?

Zebra Medical Vision has raised a total of $50M in funding. The most recent round on record is Series C.

Where is Zebra Medical Vision headquartered?

Zebra Medical Vision is headquartered in Shefayim, Israel.

When was Zebra Medical Vision founded?

Zebra Medical Vision was founded in 2014.

What industry does Zebra Medical Vision operate in?

Zebra Medical Vision operates in Healthcare, Medical Imaging, Radiology, MedTech, HealthTech, Diagnostic Imaging.

How many employees does Zebra Medical Vision have?

Zebra Medical Vision has approximately 56 people on record.

HEADCOUNT
56
DOMAIN RATING
53
Comments

No comments yet. Be the first to share your take.